Search

First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral NIM-1324 treatment confirmed as well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 validated to [...]

* BeCoMe-9 Trial Poster : Highlights ongoing Phase 1/2 trial evaluating BE-101, a first-in-class B cell medicine (BCM) designed to sustain Factor IX levels in adults with Hemophilia B. * [...]

ATHENS, Ga. & SAN JOSE, Calif. -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune [...]

* Phase 2a study to evaluate safety and immunogenicity of a booster dose of influenza vaccine candidate OVX836, three to five years after initial administration * Enrollment of over 150 [...]

MUMBAI, India & HYDERABAD, India -- PopVax, an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using machine learning-enabled computational protein design, is pleased to announce that it [...]

- Novel Investigational Combination Regimen is Advancing to Phase 3 and has the Potential to Become the First Weekly Oral HIV Treatment - FOSTER CITY, Calif., & RAHWAY, N.J. -- [...]

* New preclinical data demonstrate potential for precision-engineered B cell medicines ('BCMs') to produce active and sustained levels of tissue-nonspecific alkaline phosphatase ('ALP') * Data presented at the American Society [...]

NEW YORK -- Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced the completion of enrollment of its U.S. Phase [...]

HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the 'Company') announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical trial site in [...]

HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the 'Company') announced today that the Deltacel-01 Safety Monitoring Committee (SMC) has unanimously voted in favor of proceeding with the expansion [...]

- 99.9% of Participants Did Not Acquire HIV Infection in the Lenacapavir Group, with 2 Incident Cases Among 2,180 Participants - - PURPOSE 2 Trial Results for Cisgender Men and [...]

On track to initiate Part 2 in September HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the 'Company') reports interim results near the completion of Part 1 of its [...]

* 10 of 12 patients treated in HER2 expressing solid tumor Phase 1b trial were breast cancer patients * Dose selected for ongoing Phase 2b clinical trial in Osteosarcoma was [...]

- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were demonstrated between any dose [...]

OXFORD, England & CAMBRIDGE, Mass. -- SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced today the completion of [...]

Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial's Second Cohort [...]

* Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population HAYWARD, Calif. -- Arcus Biosciences, [...]

* 1-year Event Free Survival (EFS) of 32.5% vs. 20% 1-year EFS for comparator * Interim 1-year and 18-month Overall Survival (OS) of 90.4% * 0 Grade 3, 4 or [...]

BE-101 is the first engineered B Cell Medicine to Enter Clinical Trials for Hemophilia B Initiation of BeCoMe-9 Phase 1/2 Clinical Study Expected in the Second Half of 2024 CAMBRIDGE, [...]

CAMBRIDGE, Mass. -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim [...]

* Preclinical research demonstrates that CRISPR/Cas9-based precision B cell gene engineering coupled with artificial intelligence-guided protein design produces active tissue-nonspecific alkaline phosphatase ('ALP') * Data presented at American Society of [...]

Trial's Safety Monitoring Committee Recommends Maintaining Initial Cell Dose Level for Next Cohort of Patients HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the 'Company') reports early efficacy results [...]

* 478 participants were enrolled across Australia * Full immunogenicity and safety results expected in the second half of 2024 LYON, France -- Osivax, a biopharmaceutical company developing vaccines to [...]

Favorable Safety and Tolerability also Observed HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the 'Company') reports early efficacy results showing primary lung tumor stabilization and the complete disappearance [...]

- Week 24 Results Support Continued Development as a Potential Long-Acting Oral Combination Treatment Option in Virologically Suppressed People with HIV - - Novel Investigational Combination Regimen has the Potential [...]

Third Patient Enrolled in Deltacel-01 Completes Treatment HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the 'Company') announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as [...]

Research Published in NPJ Vaccines ATHENS, Ga. & MEMPHIS, Tenn. -- CyanVac LLC, a clinical-stage intranasal vaccine company developing PIV5-vectored vaccines that harness the full breadth of the immune system [...]

Second Patient Completed Treatment and Third Patient Dosed in Phase 1 Study Evaluating Deltacel([TM]) for the Treatment of Non-Small Cell Lung Cancer HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' [...]

Collaboration will harness Medidata Electronic Clinical Outcome Assessment (eCOA) for remote patient engagement and real-time data capture NEW YORK -- Medidata, a Dassault Systemes company and leading provider of clinical [...]

Study to assess safety and immunogenicity of novel protein nanoparticle vaccine candidates UVAX-1107 and UVAX-1197 in healthy volunteers NEWARK, Del. -- Uvax Bio, LLC, ('Uvax' or 'the Company') a privately [...]

Company Executives Available to Meet with Investment Professionals January 8-10 in San Francisco HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the 'Company'), a clinical-stage, fully-integrated biotherapeutics company using [...]

NEWARK, Del. -- Uvax Bio, LLC, a privately held, clinical-stage vaccine company, today announced acknowledgement from Australian Therapeutic Goods Administration and approval from the Human Research Ethics Committee (HREC) to [...]

Initial Tolerability and Safety Data from First Patient Expected by Year-End, with Preliminary Efficacy Results by End of January 2024 HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the [...]

SUZHOU, China -- Suzhou OSAI Biopharma, Inc., a biopharmaceutical company focused on developing live biotherapeutic products (LBPs), today announced that its Phase III clinical trial of vaginal L. crispatus live [...]

SpyBiotech's lead program is targeting human cytomegalovirus (HCMV) OXFORD, England & CAMBRIDGE, Mass. -- SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, [...]

MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%) The key secondary endpoints assessing symptom reduction, TSS50 and absolute change in TSS, showed significant improvements for intermediate-risk [...]

CAMBRIDGE, Mass. -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker [...]

First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral treatment with NIM-1324 is well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 induces a [...]

Company is Activating Additional Clinical Trial Sites Across the U.S. HOUSTON -- Kiromic BioPharma, Inc. (OTC PINK: KRBP) ('Kiromic' or the 'Company'), a clinical-stage, fully-integrated biotherapeutics company using its proprietary [...]

* A Phase 1/2a clinical trial is underway in children ages six to 59 months of age ATHENS, Ga. & LOS GATOS, Calif. -- Blue Lake Biotechnology, Inc., a clinical-stage [...]

Beverly Hills Cancer Center is the first of up to four prestigious clinical sites expected to evaluate Deltacel([TM]) (KB-GDT-01) in patients with non-small cell lung cancer HOUSTON -- Kiromic BioPharma, [...]

- PURPOSE 5 trial will evaluate lenacapavir as twice-yearly prevention option in people who could benefit from HIV pre-exposure prophylaxis (PrEP) in France and the United Kingdom - FOSTER CITY, [...]

- Black and Hispanic / Latinx people with multiple sclerosis (MS) often experience more severe disease and greater disability - - Results from the Phase IV CHIMES trial demonstrate safety [...]

The Phase I Part B will evaluate the combination of BT-001 and pembrolizumab in solid tumors, including melanoma STRASBOURG, France & LUND, Sweden -- Regulatory News: Transgene (Euronext Paris: TNG), [...]

SpyBiotech's lead program to target HCMV OXFORD, England & CAMBRIDGE, Mass. -- SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic [...]

Clinical trials will advance treatment of COVID-19 infection. BEIJING -- Sinovac Biotech Ltd. ('SINOVAC' or the 'Company') (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the [...]

* Evidence of cross-protection against multiple SARS-CoV-2 variants of concern observed in hamster challenge model LYON, France -- Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly [...]

* Australia-based Phase 2a clinical study to evaluate broad-spectrum influenza vaccine candidate, OVX836 in combination with Quadrivalent Influenza Vaccines (QIVs) * An enrollment of over 500 participants across Australia is [...]

* First clinical trial to explore the potential of imetelstat in relapsed/refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (MDS) * Data from animal pre-clinical models indicated imetelstat [...]

Treatment of all Phase Ia cohorts in monotherapy completed with no safety concerns Stabilization of injected lesions in 11/18 patients An independent Safety Review Committee has approved initiation of the [...]